CINV Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The market is segmented by Drug Type (5-HT3 inhibitors, NK1 inhibitors, Others), by End-User and by Geography.

Market Snapshot

Study Period:

2018 - 2026

Base Year:

2020

Fastest Growing Market:

Asia Pacific

Largest Market:

North America

CAGR:

5.8 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The CINV treatment market studied was projected to grow with a CAGR of nearly 5.8% over the forecast period. The major factors attributing to the growth of the market are the increasing prevalence of cancer and rising research and development activities for cancer. According to the National Institutes of Health (NIH),  in 2018, an estimated 1,735,350 new cases of cancer will be detected in the United States and 609,640 people will die from the disease. Furthermore, the growing investments in research and development programs by the biotechnology and pharmaceutical companies is boosting the market growth. However, the lack of awareness of the available drugs is the major drawback for market growth.

Scope of the Report

As per the scope of the report nausea and vomiting are the two most common side effects coupled with cancer chemotherapy and are described to as chemotherapy-induced nausea and vomiting. This report is segmented by Drug Type, by End-User, and by Geography.

By Drug Type
5-HT3 inhibitors
NK1 inhibitors
Others
By End-User
Hospitals
Specialty Clinics
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Speciality Clinics Segment is expected to Grow at a Faster rate in the Forecast Period

  • When chemotherapy penetrates the body, sensors in the digestive system and brain detect its presence as a foreign substance. Several substances, including serotonin and substance P, are released, triggering nausea and vomiting reflex. This is the body’s effort to get rid of the foreign substance. So the doctors prescribe treatment for the CINV.
  • The major factor boosting the market growth of the segment is the increasing number of cancer cases globally. As the patient pool increases, there is a growth of chemotherapy and its side effects. The oncology clinics are increasing in number and so does the market growth.
cinv-treatment-market_Estimated Number of Incident Cancer Cases, Global, 2020 to 2040

To understand key trends, Download Sample Report

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall CINV treatment market, throughout the forecast period. The market growth is due to factors such as the presence of key players, high prevalence of cancer patients in the region, established healthcare infrastructure, and availability of branded drugs are some of the key factors accountable for its large share in the market. Furthermore, beneficial government initiatives and an increase in the number of research partnerships are some of the drivers expected to increase market growth. In the North America region, the United States holds the largest market share due to the factors such as the increasing number of geriatric populations, along with a growing number of patient pools in the country.

Sugar Based Excipients

To understand geography trends, Download Sample Report

Competitive Landscape

The CINV Treatment market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market Merck & Co., Inc., GlaxoSmithKline plc, Heron Therapeutics, Inc., Helsinn Holding S.A., Baxter Healthcare, Sandoz (Novartis AG), Orchid Healthcare, Mylan Pharmaceuticals, Inc., Teva Pharmaceuticals, and Sun Pharma.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Prevalence of Cancer

      2. 4.2.2 Rising Research and Development Activities for Cancer Treatments

    3. 4.3 Market Restraints

      1. 4.3.1 Lack of Awareness of the available Drugs

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Drug Type

      1. 5.1.1 5-HT3 inhibitors

      2. 5.1.2 NK1 inhibitors

      3. 5.1.3 Others

    2. 5.2 By End-User

      1. 5.2.1 Hospitals

      2. 5.2.2 Specialty Clinics

      3. 5.2.3 Others

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Merck & Co.Inc

      2. 6.1.2 GlaxoSmithKline plc

      3. 6.1.3 Heron Therapeutics, Inc

      4. 6.1.4 Helsinn Holding S.A

      5. 6.1.5 Novartis AG

      6. 6.1.6 Baxter Healthcare

      7. 6.1.7 Orchid Healthcare

      8. 6.1.8 Mylan Pharmaceuticals, Inc

      9. 6.1.9 Sun Pharmaceutical Industries Ltd.

      10. 6.1.10 Teva Pharmaceutical Industries Ltd.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The CINV Treatment Market market is studied from 2018 - 2026.

The CINV Treatment Market is growing at a CAGR of 5.8% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

  • Merck & Co., Inc.
  • Heron Therapeutics, Inc
  • Helsinn Holding S.A
  • GlaxoSmithKline plc (Tesaro, Inc)
  • Novartis AG (Sandoz)

Are the major companies operating in CINV Treatment Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!